Details

Autor(en) / Beteiligte

• Goral, Agnieszka
• Firczuk, Malgorzata
• Fidyt, Klaudyna
• Sledz, Marta
• Simoncello, Francesca
• Siudakowska, Karolina
• Pagano, Giulia
• Moussay, Etienne
• Paggetti, Jérôme
• Nowakowska, Patrycja
• Gobessi, Stefania
• Barankiewicz, Joanna
• Salomon-Perzynski, Aleksander
• Benvenuti, Federica
• Efremov, Dimitar G
• Juszczynski, Przemyslaw
• Lech-Maranda, Ewa
• Muchowicz, Angelika

Titel

A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia

Ist Teil von

• Frontiers in immunology, 2022-02, Vol.13, p.781364-781364

Ort / Verlag

Switzerland: Frontiers Media S.A

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Regulatory T cells (Tregs) are capable of inhibiting the proliferation, activation and function of T cells and play an important role in impeding the immune response to cancer. In chronic lymphocytic leukemia (CLL) a dysfunctional immune response and elevated percentage of effector-like phenotype Tregs have been described. In this study, using the Eµ-TCL1 mouse model of CLL, we evaluated the changes in the Tregs phenotype and their expansion at different stages of leukemia progression. Importantly, we show that Tregs depletion in DEREG mice triggered the expansion of new anti-leukemic cytotoxic T cell clones leading to leukemia eradication. In TCL1 leukemia-bearing mice we identified and characterized a specific Tregs subpopulation, the phenotype of which suggests its role in the formation of an immunosuppressive microenvironment, supportive for leukemia survival and proliferation. This observation was also confirmed by the gene expression profile analysis of these TCL1-specific Tregs. The obtained data on Tregs are consistent with those described so far, however, above all show that the changes in the Tregs phenotype described in CLL result from the formation of a specific, described in this study Tregs subpopulation. In addition, functional tests revealed the ability of Tregs to inhibit T cells that recognize model antigens expressed by leukemic cells. Moreover, inhibition of Tregs with a MALT1 inhibitor provided a therapeutic benefit, both as monotherapy and also when combined with an immune checkpoint inhibitor. Altogether, activation of Tregs appears to be crucial for CLL progression.